

Osimertinib AURA3

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE




ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Osimertinib AURA3

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies  
Therapeutic Indication: As monotherapy for the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC  
Experimental Arm: Osimertinib  
Control Arm: Platinum/pemetrexed



